Altos Labs—a deep-pocketed rejuvenation company—has begun early human testing of cellular reprogramming approaches. Early safety data is reportedly under internal review. If safety holds, larger trials should follow.
Why it matters: moving from mice to humans is the hardest jump. Even safety-first trials signal confidence in the platform.
Background: Scientific American · What is epigenetic reprogramming?
